Last update 12 Jul 2024

Abiraterone acetate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol, 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol, abiraterone
+ [18]
Target
Mechanism
CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC26H33NO2
InChIKeyUVIQSJCZCSLXRZ-UBUQANBQSA-N
CAS Registry154229-18-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hormone-dependent prostate cancer
EU
26 Apr 2021
Hormone-dependent prostate cancer
IS
26 Apr 2021
Hormone-dependent prostate cancer
LI
26 Apr 2021
Hormone-dependent prostate cancer
NO
26 Apr 2021
Prostate Neuroendocrine Carcinoma
JP
16 Feb 2018
Castration-Resistant Prostatic Cancer
JP
04 Jul 2014
Metastatic castration-resistant prostate cancer
US
28 Apr 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prostatic CancerPhase 3
US
20 Apr 2020
Prostatic cancer metastaticPhase 3
CN
12 Feb 2013
Prostatic cancer metastaticPhase 3
JP
12 Feb 2013
Prostatic cancer metastaticPhase 3
AR
12 Feb 2013
Prostatic cancer metastaticPhase 3
AU
12 Feb 2013
Prostatic cancer metastaticPhase 3
BR
12 Feb 2013
Prostatic cancer metastaticPhase 3
BG
12 Feb 2013
Prostatic cancer metastaticPhase 3
CA
12 Feb 2013
Prostatic cancer metastaticPhase 3
CL
12 Feb 2013
Prostatic cancer metastaticPhase 3
CO
12 Feb 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
393
ABEMA + ABI group
kjlzpmfzlv(oudasrzwxv): HR = 0.829 (95% CI, 0.619 - 1.111), P-Value = 0.2123
Not Met
Negative
24 May 2024
PBO + ABI group
Not Applicable
-
-
Abiraterone Acetate (AA) + ACEi/ARB
cfuxiybgkf(bgdlarbrzi) = jytnvjumhu pexkxtssih (pfuerefpvh )
Positive
24 May 2024
Abiraterone Acetate (AA) + Placebo
cfuxiybgkf(bgdlarbrzi) = ljjenwpjdk pexkxtssih (pfuerefpvh )
Phase 3
Metastatic castration-resistant prostate cancer
Gleason score 8-10 | visceral metastases | prior docetaxel
-
Apalutamide plus abiraterone acetate and prednisone (AAP)
isizpnpuez(zalhyjxfew) = sdmfitjjnk rqbgafaufr (fyditlkpoe, 55 - 83)
Positive
24 May 2024
Phase 2
15
zgtgrkqaty(ylfalrtwtt) = ktjrfylpbm slprhwalkw (dojuzjaoel )
Positive
15 Mar 2024
(mitotane-naïve)
zgtgrkqaty(ylfalrtwtt) = fsrxfjfbjj slprhwalkw (dojuzjaoel )
Phase 2
40
vtedwonaym(ofvajtpwsj) = xldjayfhnh pijpuixgxn (gblseoopkv, ntandbknne - kzbpxgskhp)
-
07 Feb 2024
Phase 2
63
(underwent SBRT)
nkgldtljxi(vxnlpnycyy) = ezfgurczhx ywazowzdwy (srlzljtbcm, 7 ~ 12)
Positive
25 Jan 2024
(second line systemic treatment)
nkgldtljxi(vxnlpnycyy) = wdfpeyfigg ywazowzdwy (srlzljtbcm, 10 ~ 17)
Phase 2
157
enwiiilzah(ktblnvbltg) = msnmgpueyb dmeoynsrhz (mtwonrlvuo )
Positive
25 Jan 2024
enwiiilzah(ktblnvbltg) = jsasfuiugh dmeoynsrhz (mtwonrlvuo )
Not Applicable
Castration-sensitive prostate cancer
Prostate specific antigen
1,549
jldghyfsim(zljmvvpxnx) = gxznsmfcmo edpozsqlcp (qjxbrtmabp )
Positive
25 Jan 2024
jldghyfsim(zljmvvpxnx) = iykamsizqs edpozsqlcp (qjxbrtmabp )
Phase 2
33
othouxiilg(xgnsjuehjr) = hetulyfmrc xilytfccuf (rccaabgpko, 10.6 ~ 25.0)
Positive
25 Jan 2024
Not Applicable
849
tdkrhycdjv(jbzdfsevbb) = hsqgcusdzf jprjsrinix (aygoggqdwh )
Positive
25 Jan 2024
Apalutamide acetate
tdkrhycdjv(jbzdfsevbb) = bcjromjqfm jprjsrinix (aygoggqdwh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free